Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15819968 | 1.00 | ANPEP (0.59) | ANPEPERAP2ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL6492794 | 1.00 | ANPEP (0.59) | ANPEPERAP2ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL725878 | 0.87 | ALDH1A1 (0.72) | ANPEPERAP2ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL23367774 | 0.85 | ANPEP (0.58) | ANPEPERAP2ALDH1A1DNM1CHRM2 | |
| SCHEMBL898462 | 0.84 | ANPEP (0.66) | ANPEPERAP2ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL17238292 | 0.84 | ANPEP (0.56) | ANPEPERAP2ALDH1A1DNM1CHRM2 | |
| Hydrochloric Acid SCHEMBL30945857 | 0.84 | ANPEP (0.56) | ANPEPERAP2ALDH1A1DNM1CHRM2 | |
| SCHEMBL536888 | 0.83 | ANPEP (0.56) | ANPEPERAP2ALDH1A1DNM1CHRM2 | |
| SCHEMBL6268278 | 0.83 | CHRM2 (0.60) | ALDH1A1CHRM2LMNAMEN1KMT2A | |
| SCHEMBL3680963 | 0.83 | DNM1 (0.59) | ANPEPERAP2ALDH1A1DNM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192833-B1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2026-01-21 | — | — | EP | disclosed |
| US-12473293-B2 | Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2025-11-18 | — | — | US | disclosed |
| EP-4549438-A1 | FIVE-MEMBERED AND SIX-MEMBERED NITROGEN-CONTAINING COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024259945-A1 | NITROGEN-CONTAINING COMPOUNDS HAVING FIVE-MEMBERED RING FUSED WITH SIX-MEMBERED RING, PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州圣域生物医药科技有限公司 | 2024-12-26 | — | — | WO | disclosed |
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024002284-A1 | FIVE-MEMBERED AND SIX-MEMBERED NITROGEN-CONTAINING COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | 杭州圣域生物医药科技有限公司 | 2024-01-04 | — | — | WO | disclosed |
| CN-117304183-A | Five-membered and six-membered nitrogen-containing compound, intermediate thereof, preparation method and application | 杭州圣域生物医药科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230286988-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2023-09-14 | — | — | US | disclosed |
| EP-4192833-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2023-06-14 | — | — | EP | disclosed |
| CN-109952305-B | Piperazino heteroaryl derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-11247998-B2 | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| EP-3660018-A1 | PIPERAZINE HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE OF SAME IN MEDICINE | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2020-06-03 | — | — | EP | disclosed |
| US-20200157111-A1 | PIPERAZINE HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE OF SAME IN MEDICINE | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-05-21 | — | — | US | disclosed |
| CN-109952305-A | Piperazine and heteroaryl analog derivative, preparation method and its application in medicine | 江苏恒瑞医药股份有限公司 | 2019-06-28 | — | — | CN | disclosed |
| WO-2018148204-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2018-08-16 | — | — | WO | disclosed |
| US-6958402-B2 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-20040254164-A1 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER INC. (US) | 2004-12-16 | — | — | US | disclosed |
| US-6713496-B2 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-20030199522-A1 | 3-(Imidazolyl)-2-alkoxypropanoic acids | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199522-A1 | 3-(Imidazolyl)-2-alkoxypropanoic acids | F2, FGB, F7 | ANPEP 2110/4885ERAP2 2943/4885ALDH1A1 191/4885 |
| US-11247998-B2 | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine | IKZF2, WEE1, NOTUM | ANPEP 2016/4885ERAP2 2736/4885ALDH1A1 909/4885 |
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | ANPEP 2254/4885ERAP2 729/4885ALDH1A1 1836/4885 |
| US-20040254164-A1 | 3-(imidazolyl)-2-alkoxypropanoic acids | F2, FGB, F7 | ANPEP 2126/4885ERAP2 3045/4885ALDH1A1 217/4885 |
| US-20200157111-A1 | PIPERAZINE HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE OF SAME IN MEDICINE | IKZF2, WEE1, NOTUM | ANPEP 2016/4885ERAP2 2736/4885ALDH1A1 909/4885 |
| US-20230286988-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | GABRA5, GABRA1, P2RX5 | ANPEP 4354/4885ERAP2 3334/4885ALDH1A1 578/4885 |
| US-12473293-B2 | Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | GABRA5, GABRA1, P2RX5 | ANPEP 4354/4885ERAP2 3334/4885ALDH1A1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.